SEC Comment Letter for KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — May 9, 2019
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: May 9, 2019 · CIK: 0001372514 · Accession: 0000000000-19-008274
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231204
Letter
May 9, 2019 Stephen From President and Chief Executive Officer EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 Re:EyeGate Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 3, 2019 File No. 333-231204 Dear Mr. From: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Robert A. Petitt - Burns & Levinson LLP
Show Raw Text
May 9, 2019
Stephen From
President and Chief Executive Officer
EyeGate Pharmaceuticals, Inc.
271 Waverley Oaks Road, Suite 108
Waltham, MA 02452
Re:EyeGate Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 3, 2019
File No. 333-231204
Dear Mr. From:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Robert A. Petitt - Burns & Levinson LLP